R. Rothman, V. Bykov, B. Costa
Aug 29, 1989
Citations
1
Influential Citations
44
Citations
Quality indicators
Journal
European Journal of Pharmacology
Abstract
De Costa et al. (FEBS Lett. 223, 335; 1987) recently described the synthesis of optically pure enantiomers of (±)-trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488). In the present study we examined the in vitro opioid receptor selectivity of (−)-(1S,2S)-U50,488, (+)-(1R,2R)-U50,488 and (±)-cis-3,4-di-chloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (the cis diasteromers of U50,488), as well as their pharmacological activities in rhesus monkeys. Using [3H]5α,7α,8β-(−)-N-methyl-N-[7-1-pyrrolidinyl)-1-oxaspiro (4,5)dec-8-yl]-phenyl-benzeneacetamide([3H]U69,593) to label κ binding sites of guinea pig membranes, the apparent dissociation constants of the enantiomers hadU50,488 were 0.89 and 299 nM, for the (S,S) and (R,R) enantiomers, respectively. The (−)-cis and (+)-cis diastereomers had apparent Kds of 167 and 2715 nM, respectively. Binding surface analysis of the interaction of (−)-(1S,2S)-U50,488 with κ binding sites labeled by [3H]bremazocine resolved two binding sites at which (−)-(1S,2S)-U50,488 had Kds of 30 and 10485 nM, respectively. The (±)-cis, (−)-cis and (+)-cis diastereomers of U50,488 (1 μM) did not inhibit [3H]bremazocine binding. Rhesus monkeys were trained to discriminate ethylketocyclazocine (EKC) and saline. All compounds tested substituted completely for EKC. The order of potency was (−)-(1S,2S)-U50,488 > (±)-U50,488 > (±)-cisdiastereomerofU50,488 > (+)-(1R,2R)-U50,488. In tests of analgesia, (−)-(1S,2S)-U50,488 was 2–4 times more potent than (±)-U50,488, while (±)-cis diastereomer of U50,488 and (+)-(1R,2R)-U50,488 were inactive at the highest doses tested (32 mg/kg). Taken collectively, these data indicate that the pharmacologically active enantiomer of U50,488 is (−)-(1S,2S)-U50,488, and provide preliminary evidence for three subtypes of κ binding sites in guinea pig brain.